NEW YORK (GenomeWeb News) – French molecular diagnostics firm IntegraGen today said that revenues during the first half of 2013 increased 18 percent year over year.

The company, which develops MDx tests for autism and cancer, said that during the first six months of the year it posted revenues of €2.7 million ($3.7 million), compared to €$2.3 million a year ago. IntegraGen preannounced preliminary first-half 2013 revenues in July.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.